Dr. Martin Makary has barred pharmaceutical and regulated industry employees from serving as official voting members on FDA advisory committees to prevent corporate influence on scientific decisions.
The move aligns with Makary's promise to prioritize "radical transparency" and restore public trust by ensuring independent evaluations of new products, though industry representatives can still attend meetings…
